In This Article:
-
Total Company Sales: $1.41 billion, an 8% increase in Q1 2025.
-
TAVR Sales: $1.05 billion, a 5.4% increase over the prior year.
-
TMTT Sales: $115 million, representing about 60% growth.
-
Surgical Sales: $251 million, a 3% increase over the prior year.
-
Adjusted EPS: $0.64 for the quarter.
-
GAAP EPS: $0.62 for the quarter.
-
Adjusted Gross Profit Margin: 78.7% in Q1 2025.
-
SG&A Expenses: $466 million, 33% of sales.
-
R&D Expenses: $255 million, 18% of sales.
-
Adjusted Operating Profit Margin: 29.1% for the quarter.
-
Cash and Cash Equivalents: Approximately $3 billion at the end of the quarter.
-
Share Repurchase: $300 million repurchased in Q1 2025.
-
Full Year Sales Guidance: Increased to $5.7 billion to $6.1 billion.
-
Full Year EPS Guidance: $2.40 to $2.50.
-
Q2 2025 Sales Guidance: $1.45 billion to $1.53 billion.
-
Q2 2025 EPS Guidance: $0.59 to $0.65.
Release Date: April 23, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Edwards Lifesciences Corp (NYSE:EW) reported an 8% increase in total company sales, reaching $1.41 billion in the first quarter of 2025.
-
The company raised its 2025 TMTT sales guidance range to $530 million to $550 million, reflecting strong momentum in its transcatheter mitral and tricuspid therapies.
-
Edwards Lifesciences Corp (NYSE:EW) achieved significant milestones, including the approval of Sapien M3 in Europe, the world's first transcatheter mitral valve replacement system.
-
The company maintained its full-year total company sales growth guidance of 8% to 10%, demonstrating confidence in its strategic plans.
-
Edwards Lifesciences Corp (NYSE:EW) has a strong balance sheet with approximately $3 billion in cash and cash equivalents, providing financial flexibility for future investments.
Negative Points
-
The company faces potential impacts from tariffs and the JenaValve acquisition, which could affect future financial results.
-
Edwards Lifesciences Corp (NYSE:EW) experienced weaker procedure growth and competitive pressure in Japan, impacting sales performance in the region.
-
The company anticipates pressure on its operating margin due to the weakening dollar and announced tariffs.
-
There is uncertainty regarding the timing of the national coverage decision (NCD) for TAVR, which could impact the expansion of treatment centers.
-
The launch of the Sapien M3 mitral valve replacement system in Europe is expected to be gradual, with a focus on creating a new category and achieving excellent patient outcomes.